On this page
A surgical discussion should start with its purpose in the individual case. It may aim to relieve pressure, control a hormone-secreting lesion or obtain tissue for diagnosis. Whether surgery is appropriate depends on subtype, anatomy, clinical findings and the alternatives.
What the operation means at patient level
Many pituitary operations use a transsphenoidal approach, reaching the pituitary region through the nose and sphenoid area. An endoscope or microscope may be used. Some anatomy requires a different approach. The surgeon explains the planned route, its goals and the risks relevant to that lesion.1
Ask how the location affects the possibility of removal, the preservation of normal pituitary function and the risks your team considers most relevant. An operation discussed for one subtype should not be assumed to be the next step for another.
Four outcomes to keep separate
| Outcome | How it differs |
|---|---|
| Radiographic resection | What imaging shows about remaining visible tumor; it does not by itself establish hormone remission. |
| Biochemical remission or control | Whether the relevant hormone syndrome meets specialist criteria; control on medicines and remission after surgery are different descriptions. |
| Symptoms and vision | What changes in the person’s experience or formal visual assessment; improvement may differ from imaging or hormone findings. |
| Recurrence or regrowth | What happens over later follow-up, including after an initially favorable result. |
Nonfunctioning adenoma follow-up guidance separates imaging, endocrine and visual assessment. Acromegaly and Cushing disease guidance use their own biochemical and recurrence criteria. A report of “complete removal” should therefore lead to clarification of which outcomes have been established and which still need assessment.234
Early recovery and discharge planning
After surgery, the team monitors pituitary function and water/sodium balance as well as clinical recovery. Hormone replacement may be needed; some deficiencies are temporary and others persist. Only the treating team can decide when reassessment or a medicine change is appropriate.5
Before discharge, ask for written instructions about medicines, testing, activity, nasal care when relevant, warning symptoms and whom to contact. Confirm how to obtain urgent advice outside routine hours.
Continuing care
Follow-up asks different questions over time: whether visible tissue remains, whether a hormone syndrome persists or returns, whether pituitary function is adequate and whether vision needs reassessment. The schedule depends on the subtype, treatment and findings. Older CNS guidance supports long-term imaging after treatment of nonfunctioning adenomas, while acknowledging uncertainty about a single optimal schedule. Those recommendations are not a timetable for every functioning lesion.2
Prolactinoma follow-up has its own relationship between prolactin measurements, symptoms and imaging. Acromegaly and Cushing disease also require subtype-specific endocrine assessment. Remaining or recurrent disease can lead to another discussion about medicines, surgery or selected radiation, rather than one automatic next treatment.634
Keep copies of discharge information and ask who coordinates the endocrine, surgical and vision-related parts of follow-up. An initially favorable scan or hormone result is useful information; it is not a promise that no further care will be needed.
References
- National Cancer Institute. Pituitary Tumors Treatment. Updated 28 March 2025. Source ↩
- Congress of Neurological Surgeons. Management of Nonfunctioning Pituitary Adenomas, chapter 8: Post Treatment Follow-up Evaluation. 2016. Source ↩
- Melmed S et al. Nat Rev Endocrinol. 2025;21:718–737. doi:10.1038/s41574-025-01148-2. Source ↩
- Fleseriu M et al. Lancet Diabetes Endocrinol. 2021;9:847–875. doi:10.1016/S2213-8587(21)00235-7. Source ↩
- Endocrine Society. Hormonal Replacement in Hypopituitarism in Adults: Clinical Practice Guideline. 2016. Source ↩
- Petersenn S et al. Nat Rev Endocrinol. 2023;19:722–740. doi:10.1038/s41574-023-00886-5. Read with Author Correction, 17 October 2023. Source ↩